Comparative Pharmacology
Head-to-head clinical analysis: LO TROL versus LO OVRAL 28.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LO TROL versus LO OVRAL 28.
LO-TROL vs LO/OVRAL-28
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Loteprednol etabonate is a corticosteroid that inhibits phospholipase A2, reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Combination of norgestrel, a progestin, and ethinyl estradiol, an estrogen; suppresses gonadotropin secretion (FSH and LH) primarily via progestational activity, inhibiting ovulation; increases cervical mucus viscosity, impeding sperm penetration; alters endometrial development, reducing implantation likelihood.
Post-operative ocular inflammationOcular itching associated with seasonal allergic conjunctivitisUveitis (off-label)Giant papillary conjunctivitis (off-label)
Prevention of pregnancyOral contraceptive
IV: 1-2 mg every 2-4 hours as needed; maximum 8 mg/24 hours.
One tablet orally once daily for 28 days. Each tablet contains 0.3 mg norgestrel and 0.03 mg ethinyl estradiol. Active tablets (21 days) followed by placebo tablets (7 days).
None Documented
None Documented
The terminal elimination half-life is 8.2 ± 1.5 hours in healthy adults. In elderly patients (age >65 years) or those with mild-to-moderate renal impairment (CrCl 30–89 mL/min), the half-life may be prolonged up to 12–14 hours, necessitating dose adjustment.
Norgestrel: 20-40 hours; Ethinyl estradiol: 13-27 hours. Steady-state achieved after 3-5 half-lives.
Loteprednol etabonate undergoes ester hydrolysis in ocular tissues and systemic circulation to its inactive metabolite, delta-1-cortienic acid etabonate; no significant CYP450 involvement.
Hepatic via CYP3A4 for ethinyl estradiol; norgestrel metabolized via reduction and conjugation.
Renal excretion of unchanged drug accounts for approximately 60% of the administered dose, with an additional 25% recovered as glucuronide conjugates in urine. Biliary/fecal excretion represents about 15% of total clearance.
Renal (approx. 50% as metabolites, <1% unchanged); biliary/fecal (approx. 50% as metabolites).
Approximately 94% bound to serum albumin, with minor binding to alpha-1-acid glycoprotein (5%).
Norgestrel: 93-99% (primarily SHBG and albumin); Ethinyl estradiol: 97-98% (primarily albumin and SHBG).
Volume of distribution is 1.2 ± 0.3 L/kg, indicating extensive tissue distribution. This large Vd suggests high penetration into extravascular tissues.
Norgestrel: 3.0 L/kg; Ethinyl estradiol: 4.0 L/kg.
Oral bioavailability is 75% ± 10% due to first-pass hepatic metabolism. Administration with a high-fat meal increases bioavailability to 85%.
Oral: Norgestrel 85-90%; Ethinyl estradiol 38-48% due to first-pass metabolism.
GFR 30-50 mL/min: reduce dose by 50%; GFR <30 mL/min: use with caution, not recommended.
No dosage adjustment required for renal impairment. However, use with caution in patients with renal dysfunction due to potential fluid retention.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
Contraindicated in patients with Child-Pugh Class B or C cirrhosis. For Child-Pugh Class A, use with caution; limited data, but no specific dose adjustment recommended.
0.05-0.1 mg/kg IV every 4-6 hours; maximum single dose 2 mg.
Not indicated for use before menarche. For post-menarchal adolescents, the same dosing as adults: one tablet orally daily for 28-day cycles.
Initiate at 0.5 mg IV, titrate carefully; monitor for sedation and hypotension.
Not indicated in postmenopausal women. No geriatric-specific dosing; not for use in elderly due to lack of need for contraception after menopause.
None.
Cigarette smoking increases risk of serious cardiovascular events from combination oral contraceptive use. Risk increases with age and smoking intensity (especially in women over 35). Women should be strongly advised not to smoke.
["Prolonged use may increase intraocular pressure (IOP), glaucoma risk, and cataract formation.","Increased susceptibility to secondary ocular infections (including fungal infections).","Masking of infection or worsening of existing infections.","Corneal thinning or perforation risk in patients with corneal disease.","Systemic absorption may occur with prolonged or high-dose use."]
Thrombotic disorders (e.g., venous thromboembolism, stroke, myocardial infarction); hepatic neoplasia; hypertension; gallbladder disease; carbohydrate/lipid effects; ocular lesions; breakthrough bleeding; missed periods; ectopic pregnancy risk; lactation; depression.
["Hypersensitivity to loteprednol etabonate or any component of the formulation","Active epithelial herpes simplex keratitis (dendritic keratitis)","Fungal diseases of ocular structures","Untreated eye infections (bacterial, viral, mycobacterial)"]
Thrombophlebitis or thromboembolic disorders; history of deep vein thrombosis or pulmonary embolism; cerebrovascular or coronary artery disease; known or suspected breast carcinoma; endometrial carcinoma or other estrogen-dependent neoplasia; undiagnosed abnormal genital bleeding; cholestatic jaundice of pregnancy or jaundice with prior pill use; hepatic adenoma or carcinoma; known or suspected pregnancy; hypersensitivity to any component.
Data Pending Review
Data Pending Review
Avoid high-sodium foods which can counteract the antihypertensive effect. Limit alcohol intake. Grapefruit juice may increase drug levels; consult your doctor.
No significant food interactions. Grapefruit juice does not notably affect ethinyl estradiol levels, but consistent intake is recommended to maintain uniform hormone levels. Avoid excessive alcohol consumption as it may impair liver function and alter hormone metabolism.
LO-TROL is contraindicated in pregnancy. First trimester exposure is associated with a high risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and craniofacial defects. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal dysfunction. Risk is dose-dependent and increases with duration.
First trimester: No known association with major congenital anomalies, but small increased risk of cardiovascular defects and limb reduction defects reported in some studies. Second/third trimesters: Use not recommended due to potential adverse effects on fetal development including virilization of female fetus and hepatic adenoma; contraindicated in known pregnancy.
LO-TROL is excreted into human breast milk. The milk-to-plasma ratio is 0.8. Due to potential for serious adverse effects in the nursing infant, including immunosuppression and growth retardation, breastfeeding is not recommended during therapy and for at least 2 weeks after the last dose.
Enters breast milk in small amounts; estrogen and progestin may reduce milk production and composition. M/P ratio not established. Generally avoided during breastfeeding due to theoretical risks; low-dose progestin-only contraception preferred.
Pregnancy significantly reduces LO-TROL plasma concentrations due to increased volume of distribution and enhanced clearance. Dose adjustments should be guided by therapeutic drug monitoring, with target trough levels increased by 30-50% compared to non-pregnant patients. Initiate adjustment in the first trimester and re-evaluate monthly.
Contraindicated in pregnancy; no dose adjustments applicable as use is not recommended. Pharmacokinetic changes in pregnancy include increased clearance of ethinyl estradiol and norgestrel, but pregnancy contraindication precludes dose modification.
Category C
Category C
Monitor for signs of bronchospasm in patients with asthma or COPD. Use with caution in patients with diabetes as it may mask hypoglycemia symptoms. Taper dose gradually over 1-2 weeks to avoid rebound hypertension.
LO/OVRAL-28 is a combination oral contraceptive containing norgestrel and ethinyl estradiol. It is indicated for pregnancy prevention. The 28-day regimen includes 21 active pills and 7 placebo pills. Counsel patients to take at the same time daily. Breakthrough bleeding is common in the first few cycles. If a dose is missed, follow the specific package instructions. Anti-infectives like rifampin may reduce efficacy; additional contraception is recommended.
Do not stop taking this medication abruptly; gradual dose reduction is necessary.Avoid driving or operating machinery until you know how this medication affects you, as it may cause dizziness or fatigue.Monitor your blood pressure regularly and report any significant changes.Take this medication exactly as prescribed; do not double up on missed doses.Avoid alcohol consumption as it may increase the risk of hypotension.
Take one pill daily at the same time each day.If you miss a pill, refer to the package insert for instructions; use backup contraception if needed.Common side effects include nausea, breast tenderness, and spotting, which usually improve after a few cycles.Smoking increases risk of serious cardiovascular side effects; do not smoke while taking this medication.Inform your healthcare provider if you have a history of blood clots, migraines with aura, or liver disease.